Tempus AI (NASDAQ:TEM) EVP Erik Phelps Sells 9,464 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. This represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Erik Phelps also recently made the following trade(s):

• On Tuesday, December 16th, Erik Phelps sold 1,302 shares of Tempus AI stock. The stock was sold at an average price of $67.42, for a total value of $87,780.84.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $58.37 on Friday. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The firm has a market cap of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. The stock has a fifty day moving average price of $62.35 and a two-hundred day moving average price of $73.39. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Institutional Trading of Tempus AI

Hedge funds have recently bought and sold shares of the company. Cranbrook Wealth Management LLC acquired a new position in shares of Tempus AI in the third quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter valued at approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at approximately $27,000. GAMMA Investing LLC purchased a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $28,000. Finally, Allworth Financial LP boosted its stake in Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Wall Street Analyst Weigh In

TEM has been the topic of a number of research analyst reports. Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday. They set an “outperform” rating and a $59.00 target price on the stock. HC Wainwright reduced their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. BTIG Research boosted their target price on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Finally, Mizuho began coverage on shares of Tempus AI in a report on Thursday. They set an “outperform” rating and a $100.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $85.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.